Acne Vulgaris: Global Burden in Focus

Comments ยท 12 Views

Acne Vulgaris is a prevalent skin condition marked by the appearance of pimples, blackheads, cysts, and nodules. While it primarily affects adolescents, it can develop at any age. The disorder is caused by excessive sebum production and clogged hair follicles, which result in inflammation.

Explore key stats, market drivers, and emerging drugsall in one visual!: Click Here

Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the 7MM from 2020 to 2034 includes:

  • Total prevalent cases of Acne Vulgaris

  • Total diagnosed prevalent cases of Acne Vulgaris

  • Gender-specific diagnosed prevalent cases of Acne Vulgaris

  • Severity-specific diagnosed prevalent cases of Acne Vulgaris

  • Treatable cases of Acne Vulgaris

Acne Vulgaris Epidemiology
In 2023, approximately 140.2 million cases of Acne Vulgaris were reported in the 7MM, with the US accounting for roughly 69.5 million cases. These numbers are projected to increase throughout the forecast period.

Females represented 63% of diagnosed Acne Vulgaris cases in the 7MM, indicating a higher prevalence among women.

The severity breakdown of Acne Vulgaris cases in the 7MM is as follows:

  • Moderate cases comprised the largest proportion, accounting for 45% of diagnosed cases.

  • Severe cases were the least frequent, constituting only 10% of total cases.

Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was estimated at approximately USD 4.26 billion in 2023.

Acne Vulgaris Market Drivers
The launch of new therapies such as SB204, DMT310, and BTX 1503 is expected to enhance treatment options by offering more targeted, effective, and safer solutions for Acne Vulgaris.

Growing awareness of the condition, particularly its psychological effects, coupled with improved diagnostic capabilities, is anticipated to drive growth in the Acne Vulgaris treatment market.

Acne Vulgaris Market Barriers
The diverse clinical presentations of Acne Vulgaris and variable treatment responses, especially in moderate and severe cases, complicate therapy development and approval, leading to unpredictable treatment outcomes.

High treatment costs, notably for advanced and novel therapies, along with limited healthcare access in some regions, may hinder market growth.

One graphic, all the essentialsclick to explore!: Click Here

Acne Vulgaris Emerging Therapies

  • SB204

  • DMT310

  • BTX 1503

  • B244

  • BPX-01

  • And others

Acne Vulgaris Key Players

  • Pelthos Therapeutics

  • Dermata Therapeutics

  • Botanix Pharmaceuticals

  • AOBiome LLC

  • BioPharmX

  • Timber Pharmaceuticals

  • And others

Grab your free copy of the infographicessential for any analyst!: Click Here

disclaimer
Comments